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Smooth muscle cell (SMC) proliferation is a hallmark of vascular injury and disease. Global hypomethylation
occurs during SMC proliferation in culture and in vivo during neointimal formation. Regardless of the pro-
grammed or stochasticnatureof hypomethylation, identifying these changes is important in understanding vas-
culardisease,asmaintenance ofacells’epigenetic profile isessential formaintainingcellularphenotype.Global
hypomethylation of proliferating aortic SMCs and concomitant decrease of DNMT1 expression were identified in
culture during passage. An epigenome screen identified regions of the genome that were hypomethylated
during proliferation and a region containing Collagen, type XV, alpha 1 (COL15A1) was selected by ‘genomic
convergence’ for characterization. COL15A1 transcript and protein levels increased with passage-dependent
decreases in DNA methylation and the transcript was sensitive to treatment with 5-Aza-2′-deoxycytidine, sug-
gesting DNA methylation-mediated gene expression. Phenotypically, knockdown of COL15A1 increased SMC
migration and decreased proliferation and Col15a1 expression was induced in an atherosclerotic lesion and
localized to the atherosclerotic cap. A sequence variant inCOL15A1 that is significantly associated with athero-
sclerosis (rs4142986, P 5 0.017, OR 5 1.434) was methylated and methylation of the risk allele correlated with
decreased gene expression and increased atherosclerosis in human aorta. In summary, hypomethylation of
COL15A1 occurs during SMC proliferation and the consequent increased gene expression may impact SMC
phenotype and atherosclerosis formation. Hypomethylated genes, such as COL15A1, provide evidence for
concomitant epigenetic regulation and genetic susceptibility, and define a class of causal targets that sit at
the intersection of genetic and epigenetic predisposition in the etiology of complex disease.
INTRODUCTION
Vascular smoothmuscle cells (SMCs) are an essential structural
component of the artery and provide the necessary contractile
function tomaintain bloodflow(1).The cells themselves layqui-
escent until activated by a number of events at the onset of
atherosclerosis (2). Activation leads to SMC proliferation and
migration into the intima and through a complex cascade of
events involving multiple cell types ultimately the production
of an atherosclerotic plaque (2). SMCs have the ability to
change between different phenotypic states (3), and thus, play
a number of roles in vessel stability and disease. Therefore,
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these cells make for an exquisite model for the study of epigen-
etic changes associated with their phenotypic plasticity and
disease.
One of the key features of a stable atherosclerotic plaque is the
presence of a SMC-rich fibrous cap (4,5). SMCs isolated from the
atherosclerotic plaque and fibrous cap are pre-senescent (6) and
globallyhypomethylated (7).Assuch, theyexhibit reducedprolif-
erative capacity and lifespan (8). The pre-senescent state can be
achieved through multiple rounds of SMC replication in vitro
(6) and comparison of early and late replicated cells has served
as a model of SMC replicative aging (6,9,10). In addition, like
all cells that lack telomerase activity, SMCs have a lifespan that
is limited by the number of cell divisions, resulting in replicative
senescence (11). Cell division requires the faithful replication of
epigenetic marks such as histone modifications and DNAmethy-
lation, a process that cells undergoing replicative senescence do
inefficiently (12–15).
Proliferation of SMCs has been linked to changes in DNA
methylation, and these changes have been implicated in early
atherosclerosis formation and coronary artery disease (CAD)
(9,16,17). This process has also been likened to the proliferative
state of cancer cells within a solid tumor (18). We hypothesized
that DNA methylation changes in the proliferating SMC could
regulate SMC phenotype, and that genetic variability within
regions of DNA methylation change could account for some of
the phenotypic variability and complexity of atherosclerosis.
To test this hypothesis and initially characterize genomewide
SMC DNA methylation, we sought to identify differential pat-
terns of DNA methylation in replicating, pre-senescent SMCs.
We report herein regions of the genome that change DNA
methylation state with SMC passage. Second, we have charac-
terized a novel atherosclerosis gene, COL15A1, involved in
SMC phenotype that is regulated by epigenetic state in passaged
cells and present in atherosclerotic tissue. Finally, we have iden-
tified a common polymorphism associated with atherosclerosis
in aged individuals that resides in an epigenetically regulated
region of COL15A1 and show that its epigenetic modification
correlates with the disease state.
RESULTS
Replicative senescence as a model of SMC aging
Aortic SMCs (AoSMCs) isolated from a 22-year-old male Cau-
casian (6F3685) were obtained frozen at Passage 3 from Lonza
after undergoing eighteen population doublings (PDs). Cells
were plated, counted and allowed to grow for 3 days to
recover. These proliferating cells were then plated at 3500
cells per cm2 in triplicate and grown to 80% confluence, which
equated to 96 h in culture during exponential growth. This
process was repeated until cells no longer reached 80% con-
fluency. The first time point measured in triplicate was at
Passage 5 (p5) and the lastwas at p17 (Fig. 1). In order to identify
the molecular changes that lead to senescence, we sought to
obtain cells that were at early, pre-senescent states of aging.
To do this, senescence was monitored by evaluating cell
growth and cyclin D1 (CCDN1) gene expression, a known
marker of SMC senescence and the pre-senescent state (19).
As previously reported (19), changes in cell proliferation were
apparent at 35–40 PDs (Fig. 1A, arrow), whereas CCDN1
levels displayed a significant 8-fold increase between p5 and
p8consistentwith a criticalmolecular change to theproliferating
cells between 20 and 30 PDs (Fig. 1B). We hypothesized that
global change inDNAmethylationmaybe an importantmolecu-
lar event that takes place before cells senesce, and that this
change may be apparent by p8. We assayed global methylation
levels in passaged SMCs using the LUMA assay (20) and
detected a significant loss of methylation (5% of 2.4 million
CpG sites assayed (21)) between p5 and p8 (Fig. 1C). We repli-
cated this change in a genetically unique AoSMC line (7F4356)
derived from a 21-year-oldmale Caucasian (Fig. 1D). Concomi-
tantly, we identified a decrease in expression of themaintenance
methyltransferase DNMT1 at both the transcript (Fig. 1E) and
protein levels (Fig. 1F). We have thus categorized p5 and p8 as
youngandaged, respectively, and refer to the assay as replicative
aging.
A screen for epigenetic changes with SMC replicative aging
Wesought to identify regions of the genome that change theDNA
methylation state with SMC replicative aging. We hypothesized
that DNA methylation changes associated with contextural
aging in tissue are pivotal to the development of a complex
disease. In order to identify these changes, we conducted an
epigenome-wide screen for changes in DNA methylation with
SMC replicative aging using a restriction enzyme-basedmethod-
ology (22). Briefly, DNA isolated from the previously character-
ized young and agedAoSMCswas subject to sequential digestion
withSmaI andXmaI.XmaI adaptorswere ligatedon toXmaI ends,
which represent methylated CG sites in the context of CCCGGG
sequence across the genome.Young and aged sampleswere amp-
lified, labeled and cohybridized to a humanBACmicroarray (23).
Three biological replicates of the same genetic background were
assayed and hybridization of the young samples to themselves
served as the baseline control.As this experimentwas exploratory
in nature, an a priori threshold of P ≤ 0.01 (two-tailed t-test) was
used to detect significantly differentially methylated regions
between young and aged cells without correction for multiple
comparisons. The genes within these regions were mapped to
the human genome assembly hg18/build36. A total of 344
regions were detected to change with AoSMC replicative age
(P, 0.01, two-tailed t-test).Of thatgroup,176werehypermethy-
lated and 168were hypomethylated in aged cells (Supplementary
Material, Table S1).
Gene expression changes with aortic SMC
replicative age and chemical demethylation
We hypothesized that candidates that show changes in genome
level DNA methylation would also show concomitant changes
in gene expression. As such, RNA isolated from young and
agedSMCswas subjected togene expression analysis by Illumina
beadchip hybridization (48 687probes assayed). Three biological
replicates of the same genetic background were assayed for both
young and aged SMC groups. In addition, each set of young and
aged cells was treated with 5-Aza-2′-deoxycytidine, a DNA
demethylating agent, and RNA was isolated and assayed on the
same bead chip as the other samples. Chemical demethylation
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allows for the identification of loci that are potentially under the
control of DNA methylation (direct or indirect), thus adding an
additional level of candidate validation. The number of DNA
methylation changes in the genome for this assay far exceeds
the number of gene expression changes possible, therefore our a
prioriP-value cutoffwas set higher atP ≤ 0.05 for these analyses.
A comparison of gene expression changes between young and
aged aortic SMCs identified 64 significant changes (P, 0.05,
two-tailed t-test) in gene expression representing 60 genes (Sup-
plementary Material, Table S2); none of which met Bonferroni
correction (a ¼ 0.05, a′ ¼ 1.03 × 1026). A comparison of gene
expression changes between 5-Aza-2′-deoxycytidine-treated
(p5Aza) and -untreated cells (p5) identified 3301 probes that
increased significantly with treatment in the young cells (P,
0.05, two-tailed t-test) (Supplementary Material, Table S3).
Nine hundred and nine probes met Bonferroni correction (a ¼
0.05, a′ ¼ 1.03 × 1026). A comparison of gene expression
changes between 5-Aza-2′-deoxycytidine-treated (p8Aza) and
-untreated cells (p8) identified 348 probes that increased signifi-
cantly with treatment in the aged cells (P, 0.05, two-tailed
t-test) (Supplementary Material, Table S3). Thirty-nine probes
met Bonferroni correction (a ¼ 0.05, a′ ¼ 1.03× 1026). Three
hundred and forty-five probes overlapped between the two
groups, indicating that themajorityofepigenetic changesdetected
with passage were hypomethylation events.
Genomic convergence identifies COL15A1
as an epigenetically regulated target of aging
Wecombinedgene lists sortedbyuncorrectedP-values fromeach
experiment described (DNA methylation, gene expression
changes with passage and gene expression changes with hypo-
methylation in young or aged cells) with a list of genes that
change with disease in human aorta (24). A single gene,
COL15A1, exhibited significant loss of DNA methylation and
increased gene expression with atherosclerosis and age, as well
as a response to 5-Aza-2′-deoxycytidine in young cells (summar-
ized inTable 1).Thiswas the only gene of the group thatmet all of
the criteria. To assess significance across experiments, a
meta-analysiswasperformedcombiningP-values fromthediffer-
ential methylation and passage expression experiments. Because
the measures of expression and methylation are different in each
dataset and the anticipated effects and effect sizes are very differ-
ent in the twodatasets,wecreateda summarymeasureofevidence
across the two datasets using Fisher’s formula to combine
P-values for heterogeneous datasets (25). Five genesmet Bonfer-
roni significance (Table 1, bold line) including COL15A1. This
suggests that epigenetic and gene expression changes in
COL15A1 occur with replicative age and atherosclerosis, and
that we have uncovered a novel molecule that may be involved
in SMC phenotype and atherosclerosis.
Figure1.ProliferatingaorticSMCsexhibit earlymolecular signsof senescence. (A)AorticSMCsweregrowninculture in triplicateunderproliferatingconditionsand
passaged when cells reached 80% confluence. PD with time was calculated. Arrow indicates first change in cell growth between 35 and 40 PDs. (B) Cyclin D1
(CCDN1) transcript levels were assayed by passage to assess changes in the senescent state. (C) Global DNA methylation level was measured by a LUMA
assay by passage and (D) in a second AoSMC line for validation. (E) DNMT1 transcript level and (F) protein level was measured in the AoSMC validation line.
A representative western blot is shown for DNMT1 and loading control b-actin. §P, repeated measures ANOVA, Bonferroni’s multiple comparison test
∗P, 0.05, ∗∗P, 0.01; †P, paired t-test, two-tailed.
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Validation of COL15A1 epigenetic and expression changes
To verify ourDNAmethylation results, bisulfite-cloned sequen-
cing was performed on young and aged aortic SMCs at the 33
SmaI (CCCGGG) sites contained within the clone containing
COL15A1 (Chr9tp-4G1) that was identified in the DNA methy-
lation screen (Fig. 2A). No fewer than 20 clones were sequenced
for each sample and site (Supplementary Material, Table S4).
This analysis identified 13 sites that lost methylation with age;
however, two regions contained groups of sites: 6, 8, 9; and 30,
31, 32 (underlined in Fig. 2D), where at least two SmaI sites
that changed were within 3000 bp of one another, allowing for
the amplification of a double stranded molecule in the assay
used to screen the genome. These sites cluster in two regions
of the gene: upstream of the transcription start site (sites 6, 8
and 9) and at the 3′ end of the gene within the introns that sur-
round exon 31 (sites 30 and 31); site 32 falls within exon 35.
We also performed quantitative real-time PCR (RT-PCR) to
detect COL15A1 gene expression changes with age (Fig. 2B)
and with 5-Aza-2′-deoxycytidine treatment (Fig. 2C). We vali-
dated these changes in a second SMC line previously described
and show hypomethylation with passage at sites 8 and 32
(Fig. 2E) with concomitant changes in transcription (Fig. 2F)
and protein levels of COL15A1 (Fig. 2G). The directionality
of the gene expression and DNA methylation changes suggests
that hypomethylation of COL15A1 can lead to increases in
gene expression with replicative age in SMCs.
COL15A1 levels affect aortic SMC phenotype
In ourmodel of replicative aging, aging of SMCs requires prolif-
eration; therefore, we hypothesized that COL15A1 levels may
regulate the proliferation of SMCs, thus changing the migratory
state of the cell. To test this hypothesis we reduced the levels of
COL15A1 in the cell using siRNA (Fig. 3A andB) and compared
the proliferative andmigratory abilities of these cells to a knock-
down control that expresses COL15A1 at normal levels. Cells
with decreased levels of COL15A1 displayed a reduction in pro-
liferation (Fig. 3C) and an increase in migration to fibronectin
(Fig. 3D). These data indicate that levels of COL15A1 are im-
portant for key smooth muscle phenotypes.
COL15A1 expression increases in atherosclerotic lesions
Male Apoe null mice were fed a Western diet for 13 weeks to
advance atherosclerosis. Similarly, C57BL/6 mice were fed a
chow diet for the same period. Aortas were harvested and quan-
titation of Col15a1 transcript levels in aorta and liver (n ¼ 5) of
wild-type or Apoe null mice confirmed that vessels with disease
have higher levels of Col15a1 compared with a tissue not
involved with vessel atherosclerosis (liver) (Fig. 4A). This was
also true in human atherosclerotic vessels (n ¼ 88) (Fig. 4B).
These data provide in vivo evidence for the increase of
COL15A1 transcript in response to atherosclerotic disease
formation.
Table 1. Meta-analysis of candidate genes that change methylation with SMC age and atherosclerosis
Genename Clone name Chromosome
position (hg19)
Clone
methylation
P-value
Aorta
expression
P-value
SMC p5 v p8
expression
P-value
Decitabine
expression
P-value
Meta-analysis
P-value
FDXR Chr17tp-12D6 chr17:72752767-72973410 0.003 , 0.001 0.713 3.678E238 7.900E2101
FDXR Chr17tp-3E10 chr17:72755352-72928265 0.009 , 0.001 0.713 3.678E238 3.551E299
ILF3 Chr19tp-2B6 chr19:10659649-10837601 0.009 , 0.01 0.387 4.171E208 4.330E213
COL15A1 Chr9tp-4G1 chr9:101666190-101848490 0.009 < 0.05 0.031 8.517E207 1.128E212
SCP2 Chr1tp-27H8 chr1:53305823-53420058 0.001 , 0.05 0.219 5.431E206 3.442E211
SRC Chr20tp-7D9 chr20:35834692-36001722 0.009 , 0.05 0.832 1.933E206 3.522E209
CUX1 Chr7tp-4A2 chr7:101389746-101602926 0.001 , 0.001 0.073 2.550E202 1.020E205
MXRA7 Chr17tp-3A10 chr17:74597354-74758571 0.001 ,0.001 0.504 1.026E202 3.282E205
OAT Chr10tp-12A6 chr10:126018450-126199404 0.009 ,0.001 0.565 1.860E203 1.238E204
IGFBP4 Chr17tp-10D10 chr17:38465526-38637706 0.001 ,0.05 0.057 4.580E201 8.327E204
SKP1 Chr5tp-22E12 chr5:133317466-133505837 0.003 ,0.05 0.961 1.600E202 9.354E204
PSMB7 Chr9tp-3E12 chr9:126966658-127144068 0.002 ,0.05 0.628 3.254E202 9.627E204
TNRC6B Chr22tp-8E6 chr22:40465006-40493898 0.004 ,0.05 0.576 2.765E202 1.855E203
AGAP1 Chr2tp-24E1 chr2:236878894-237041900 0.001 ,0.05 0.849 5.907E202 1.913E203
FGL2 Chr7tp-5B12 chr7:76653720-76848379 0.003 ,0.01 0.251 9.569E202 2.307E203
MFN2 Chr1tp-25F3 chr1:11983047-12107571 0.008 ,0.05 0.160 2.007E201 9.114E203
PMM1 Chr22tp-8E7 chr22:41894136-41999953 0.002 ,0.01 0.356 4.807E201 1.283E202
PEX3 Chr6tp-16H5 chr6:143702511-143834084 0.002 ,0.05 0.607 4.090E201 1.999E202
GPR161 Chr1tp-31E9 chr1:167986178-168084802 0.005 ,0.05 0.175 7.304E201 2.349E202
LILRB3 Chr19tp-8A11 chr19:54527514-54723456 0.001 ,0.01 0.896 7.791E201 3.335E202
SYK Chr9tp-4A4 chr9:93520347-93708269 0.006 ,0.05 0.376 5.270E201 4.598E202
MRPL33 Chr2tp-4F10 chr2:27799947-28002099 0.002 ,0.001 0.940 7.105E201 4.600E202
RHOQ Chr2tp-10A8 chr2:46693747-46873151 0.005 ,0.05 0.594 4.951E201 4.785E202
HTR2B Chr2tp-31A3 chr2:231840654-231999694 0.006 ,0.05 0.951 2.826E201 5.565E202
CD3E Chr11tp-17H10 chr11:118065102-118257538 0.005 ,0.01 0.371 8.433E201 5.888E202
LILRB3 Chr19tp-2B12 chr19:54668579-54771282 0.003 ,0.01 0.896 7.791E201 7.671E202
HTR2B Chr2tp-17C10 chr2:231817067-231997557 0.009 ,0.05 0.951 2.826E201 7.980E202
UBE2E3 Chr2tp-17B3 chr2:181866626-182017989 0.008 ,0.05 0.915 3.430E201 8.028E202
ATP10A Chr15tp-11D10 chr15:25878086-26048915 0.009 ,0.05 0.33 7.80E201 8.08E202
Bold indicates gene chosen for follow up studies; Bold line indicates regions that survive Bonferroni correction.
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COL15A1 is expressed in SMC rich regions
of the aorta and fibrous cap
In order to determine the expression pattern of Col15a1 in an
intact vessel and in the context of atherosclerosis, we isolated
the aortic root from a mouse model of diet-induced atheroscler-
osis and control mice. Male Apoe null mice were fed a Western
diet for 18 weeks to advance atherosclerosis. Similarly, C57BL/
6micewere fed a chowdiet for the sameperiod.Aortaswere har-
vested, and the aortic root sectioned and stained for an SMC
marker (Acta2) or Col15a1 (Fig. 5). Staining showed that both
Acta2 and Col15a1 were expressed in similar regions of the
SMC rich media in control mice (Fig. 5A and B). Western diet
fed Apoe null mice displayed atherosclerotic plaque formation,
medial Acta2- and Col15a1-positive cells as seen in controls,
and a cap predominantly constituted of Acta2- and Col15a1-
positive cells (Fig. 5C and D). Localized expression of the
protein in the lesion cap may suggest an important protective
role for COL15A1 in lesion stability.
Polymorphisms in COL15A1 are associated
with atherosclerosis
Given the effects of COL15A1 levels on smooth muscle pheno-
type, we hypothesized that sequence variants within COL15A1
that affect transcription of the molecule may also be associated
with atherosclerosis. We identified 42 variants with low linkage
disequilibrium (LD) that represent the known common genetic
variation in the COL15A1 gene and assayed them in a well-
characterized sample of aged atherosclerosis (CATHGEN) (26).
Approximately 500 Caucasian individuals aged .55 years were
genotyped for genetic association analysis using an additive
model to identify variants that are over-represented in individuals
with atherosclerosis (Table 2). Cases and controlswere chosen on
the basis of extent ofCADasmeasured byCAD index (CADi, see
Methods).We identified one variant (rs4142986, P ¼ 0.017) that
was significantly associated with atherosclerosis and one variant
(rs1413298, P ¼ 0.052) with borderline significance by logistic
regression after adjusting for sex and known CAD risk factors
Figure 2. Identification of COL15A1 as a gene that is epigenetically regulated in smooth muscle replicative aging. (A) The clone containing COL15A1 exhibits
decreased methylation with passage. This was assessed by microarray hybridization of p5, p6, p7 and p8 methylated DNA and displayed as fold change (log2[p8/
p5]). (B) COL15A1 gene expression was measured by RT-PCR with age of SMC (n ¼ 3) and normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). (C) NormalizedCOL15A1 gene expressionwasmeasured byRT-PCR in both young and aged cells in the absence and presence of a demethylating chem-
ical, 5-Aza-2′-deoxycytidine (Aza). Datawere normalized toGAPDH. (D) A schematic of the clone containingCOL15A1 identified in a screen for genes that change
DNAmethylationwith SMC age. The start codon (ATG) is containedwithin the first exon; exons are denoted as black discs and introns as lines. SmaI sites contained
within this region are denoted by a black vertical line. Groups of SmaI sites that are hypomethylated with age are underlined. (E) Bisulfite cloned sequencing results
from two passaged AoSMCs lines. Indicated sites are part of the two underlined clusters in the gene schematic. (F) Validation ofCOL15A1 expression changes with
passage in second AoSMC line (7F4356). (G) Total cellular COL15A1 protein levels were assayed in young (p5) and aged (p8) SMCs by western blot. Quantitation
(n ¼ 3) was performed on a LI-COR Odyssey Infrared Imaging System. Data were normalized to b-actin (ACTB). A representative western blot is shown for
COL15A1 and loading control b-actin. §P, repeated measures ANOVA, ∗Bonferroni’s Multiple Comparison test P, 0.05; ∗∗P, 0.01. †P, paired t-test (n ¼ 3),
two-tailed.
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(history of hypertension, history of diabetes mellitus, body mass
index, history of dyslipidemia and smoking history). The
rs4142986variant isnot instrongLDwithanyof theothervariants
tested. The maximum r2 observed for rs4142986 is with
rs1413298 (r2 ¼ 0.2), raising the possibility that the association
seen for rs1413298 may be due to this very low level of LD
with rs4142986. Interestingly, both of these variants fall within
a CpG site and, therefore, have the potential to be methylated.
However, only one of these variants, rs4142986, also reside
within one of differentially methylated regions we defined in
our epigenetic screen (between SmaI sites 30 and 31, see Figs 2
and 6A). We hypothesized that the methylation state of the risk
allele (C allele) of rs4142986 could play a role in expression of
COL15A1, and that this could explain its association with
disease. That is, if increased COL15A1 expression is atheropro-
tective, thenmethylation of rs4142986may lead to decreased ex-
pression and make an individual more prone to disease.
The risk allele of rs4142986 is associated with
a reduction in COL15A1 gene expression in human
aorta and its methylation level is correlated with
early atherosclerotic disease
In order to test the hypothesis that rs4142986 could play a causa-
tive role in the development of atherosclerosis by changing
COL15A1 gene expression, we genotyped rs4142986 in 88
human aorta samples and assessed COL15A1 expression levels
in relation to genotype (Fig. 6B). Carriers of the rs4142986_C
risk allele exhibit significantly decreased (P ¼ 0.003) levels of
COL15A1, indicating that this polymorphism, or an SNP in LD
with it, may control COL15A1 gene expression. The risk
variant is a C/G SNP that resides in a CG site in the 30th intron
of COL15A1. This SNP is located 33 bp downstream of the
CpG site in SmaI site 30, which is a part of the cluster of sites
in the 3′ end of the gene identified to change methylation
status with age. We therefore hypothesized that the C allele of
rs4142986 could be methylated, and that its methylation level
would correlate with disease severity. DNA methylation was
assessed at rs4142986 in aorta samples that were scored for
disease using Sudan IV staining as a measure of lipid in the
vessel (24). We identified samples with each rs4142986 geno-
type and performed bisulfite cloned sequencing to assess the
methylation levels in C/G and C/C individuals. DNA methyla-
tion was highest in C/C individuals, intermediate in C/G indivi-
duals, and not found inG/G individuals. The level ofmethylation
correlated with the extent of disease; C/C individuals are the
most methylated and most diseased (Fig. 6C).
DISCUSSION
We report the results of a convergent analysis of genome-wide
gene epigenetic and expression screens in aortic SMCs that
Figure 3. COL15A1 levels modify SMC phenotype. (A) Human AoSMCs (7F4356) were transfected with siCOL15A1 or siControl and the level of COL15A1
(A) gene expression normalized to Beta-2 Microglobulin (B2M) and (B) protein expression normalized to b-actin (ACTB) were measured. A representative
western blot is shown for COL15A1 and loading control b-actin. (C) COL15A1 control or knockdown cells were assayed for proliferation using the MTS assay
fromPromega.Datawere normalized to the siControl. (D)COL15A1 control and knockdowncellswere assayed for their ability tomigrate through a permeablemem-
brane in response to fibronectin. †P, paired t-test (n ¼ 3), two-tailed.
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identified a novel atherosclerosis susceptibility gene,COL15A1.
We show that regions within and flanking COL15A1 change
DNA methylation with replicative aging of SMCs, and that a
polymorphism associated with atherosclerosis in aged indivi-
duals falls within one of these epigenetically regulated regions.
This SNP, rs4142986, resides within a CpG site at which the
methylation status is associated with atherosclerotic disease.
Finally, we provide evidence that COL15A1is implicated in
SMC phenotype by inversely modulating the cells ability to
proliferate and migrate. These experiments demonstrate the
Figure 4.COL15A1 expression increases with atherosclerosis. (A)Col15a1mRNA levels were measured by RT-PCR in thoracic aorta or liver taken fromwild type
(C57/BL6) chow-fedmice (n ¼ 5) orApoenullmice (n ¼ 5) after 13weeks of a high fatWestern diet feeding.Expression ofCol15a1 in the thoracic aorta but not liver
is significantly increasedwith accelerated atherosclerosis (high fat diet feeding in anApoe null background). (B)Microarray gene expression data forCOL15A1 from
aorta tissue with disease (Cases, n ¼ 26) or without disease (Controls, n ¼ 62). Disease was quantitated using Sudan IV staining for lipids and by counting raised
lesions. Controls showed neither lipid staining nor raised lesions. ∗P, unpaired t-test, two-tailed. ‡P, mixed model (see methods). 1microarray data normalization
provided in methods.
Figure5.Col15a1 is expressed inSMCs in themouseaorta.Transverse sectionsof the aortic rootwere taken fromawild-typeC57BL/6chow-fedmouse (A andB) or a
mouse model of atherosclerosis (C57BL/6 Apoe null) fed a high fat Western diet (C and D). Eighteen weeks of Western diet feeding in the Apoe null background
induced atherosclerosis (A versus C). Regions boxed in A and C are shown enlarged in B and D, respectively. Scale is indicated in yellow. Four micron sections
were stained with an antibody to smooth muscle alpha actin (Acta2) or Col15a1.
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feasibility of in vitro epigenetic and expression screening for a
cellular phenotype can lead to the identification of novel genes
and causative alleles for complex human disease research.
Known role of collagen type XV alpha 1
COL15A1 is a non-fibrillar member of the collagen superfamily
that self-trimerizes via a central triple helix domain (27,28). This
molecule is found in the basement membrane of many tissues
(29,30) and forms bridges between large collagenous bundles
in vivo (31). Although the exact cellular role of COL15A1 is
unclear, its location and bridging ability suggest a role for the
full-length protein in the stability of cellular matrices, allowing
for resilience to mechanical forces (31). A conventional knock-
out of Col15a1 exhibits subtle, complex phenotypes in both the
cardiovascular and nervous systems (32–35). The mice are
viable; however, under exercise-induced stress, they develop
heart failure, muscle atrophy, and capillary rupture (32). Under
normal conditions, thesemice exhibit a lowered cardiac ejection
fraction at 1 month, which is compensated for by 5 months, in
addition to poor capillary perfusion, which persists throughout
the lifetime of the mouse (34). In addition, the capillaries in
cardiac muscle are tortuous and prone to rupture, which is
most likely a function of the impaired basement membrane for-
mation (32,34). Purified recombinant COL15A1 also has
demonstrated effects on cell (fibrosarcoma HT1080 cells) adhe-
sion and migration (36). The addition of COL15A1 to a BSA
(bovine serum albumin )/fibronectin coating on cell culture
plates or a transwell plate significantly decreased the adhesion
and migration of human fibrosarcoma cells, respectively (36).
Intriguingly, COL15A1 also produces a cleavage product
called restin that shares 72% identity with COL18A1’s endosta-
tin molecule (37). Injections of recombinant mouse endostatin
significantly reduce angiogenesis and tumor growth in a mouse
Table 2. Association analysis of SNPs in COL15A1
Controls Cases
tagSNP PROBE P-value Odds
ratio
Individuals
assayed
Minor
allele
Minor allele
frequency (%)
Individuals
assayed
Minor allele
frequency
Minor allele
frequency (%)
1 RS932670 0.103 0.714 275 C 14.7 214 C 11.9
2 RS7874187 0.606 1.077 281 G 37.2 215 G 40.0
3 RS12379516 0.681 1.100 281 C 10.1 223 C 11.7
4 RS4743294 0.359 1.153 272 A 29.0 213 A 31.9
5 RS10819454 0.165 1.480 282 C 6.4 220 C 8.0
6 RS10819456 0.117 1.573 279 T 5.9 223 T 8.1
7 RS7470221 0.131 0.810 281 C 47.9 221 C 46.2
8 RS13288865 0.755 1.083 282 G 7.4 221 G 7.7
9 RS17710605 0.876 0.961 276 G 9.2 216 G 7.9
10 RS10819460 0.246 1.268 282 C 14.5 221 C 15.8
11 RS17783501 0.247 0.842 274 C 37.6 212 C 36.1
12 RS7045933 0.362 1.155 277 T 30.9 221 T 31.7
13 RS6478963 0.487 1.112 280 C 29.8 221 C 31.7
14 RS1413294 0.612 1.092 281 G 20.3 217 G 21.4
15 RS2050257 0.394 0.879 277 A 38.3 217 A 34.8
16 RS4743299 0.167 1.239 282 T 25.5 222 T 28.4
17 RS4743300 0.759 1.045 279 T 35.1 222 T 35.4
18 RS882727 0.445 0.851 279 A 13.6 220 A 13.2
19 RS882728 0.992 1.002 281 G 26.2 221 G 25.1
20 RS10819537 0.305 1.176 282 T 27.5 220 T 29.8
21 RS1572136 0.507 1.108 276 C 28.3 220 C 29.3
22 RS7027650 0.840 0.971 280 T 39.8 221 T 38.5
23 RS4743301 0.736 1.090 280 T 8.4 220 T 8.6
24 RS989392 0.495 1.134 280 A 16.4 222 A 17.3
25 RS2416664 0.943 0.985 278 T 12.4 221 T 12.2
26 RS3780622 0.374 0.860 283 C 22.3 221 C 19.9
27 RS1889268 0.629 0.928 280 C 32.7 219 C 30.1
28 RS10819587 0.327 0.787 277 A 10.8 220 A 9.1
29 RS1041631 0.430 0.856 282 A 16.5 220 A 14.5
30 RS12352939 0.674 1.096 279 T 11.1 222 T 11.9
31 RS7028686 0.652 1.088 280 G 14.6 221 G 15.4
32 RS4742755 0.563 0.883 281 G 13.3 221 G 12.9
33 RS12684946 0.085 0.637 280 A 9.1 221 A 7.0
34 RS17711860 0.514 1.137 283 G 13.4 220 G 14.1
35 RS869776 0.496 0.889 278 G 23.9 219 G 22.6
36 RS12352174 0.528 1.134 282 G 14.4 220 G 15.0
37 RS12216916 0.323 0.800 280 T 12.0 221 T 10.0
38 RS4142986 0.017 1.434 280 C 30.5 219 C 37.0
39 RS11789689 0.108 0.689 282 A 11.3 222 A 9.7
40 RS7047475 0.305 0.827 280 G 21.1 221 G 19.5
41 RS1413298 0.052 0.738 281 C 32.7 221 C 27.4
42 RS7040869 0.827 0.954 281 A 13.9 219 A 13.2
Bold indicates significantly associated SNP.
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orthotopic injection model (38), and overexpression of human
COL15A1 in cervical carcinoma cells completely ablates their
tumorigenicity (39). Although both restin and endostatin have
interesting antitumor effects, it is not yet knownwhether the pre-
viously described adhesive and migratory effects of COL15A1
on human fibrosarcoma cells are due to the full-length collagen,
or to this cleavage product. The current literature is mixed on
whether recombinant mouse restin has anti-proliferative or anti-
migratory effects on endothelial cells (40,41). This is clearly a
rich avenue for further research, and COL15A1 or more likely,
restin, may be a novel target for drug therapy for atherosclerotic
diseases.
SMC-specific expression of COL15A1
The expression of Col15a1/COL15A1 in SMCs is of particular
interest in the context of atherosclerosis. The process by which
SMCsmigrate from the media into the intima, and subsequently
through the forming plaque to form a stabilizing fibrous cap
(3,42–44), is dependent on extracellular matrix components
(45). COL15A1 is an extracellular matrix protein that affects
both the proliferative and migratory phenotypes of proliferating
SMCs, indicating that it may play an important role in the initi-
ation of atherosclerosis. Its presence in the fibrous cap further
suggests a role in stabilization and potential control of SMC
phenotype. Given the weight of these data, we propose that epi-
genetic changes associatedwith replicative senescence of SMCs
can control the phenotypic state andmay play an essential role in
SMC activation in the development of atherosclerosis.
The intersection of genetic and epigenetic susceptibility
in atherosclerosis
It is clear that genetic predispositionplays a significant role in the
etiology of complex disease. It is also increasingly apparent that
epigenetic changes contribute to the pathophysiology of disease
development (46). However, chronic diseases such as obesity,
atherosclerosis and diabetes, rather than being caused by these
individual mechanisms, may also be partly driven by the inter-
section between the altered chromatin structure and their herit-
able genetic components (46). Our approach began with the
integration of genome-wide epigenetic and expression data to
identify the molecular and cellular mechanisms underlying
complex disease in an etiologically relevant tissue using a
cellular model of age-related atherosclerosis. A single gene,
COL15A1, satisfied numerous a priori molecular criteria at
nominal significance levels. Further, we carried out genetic ana-
lysis and identified significant association of a nucleotide poly-
morphism that falls within a methylated CpG dinucleotide that
is differentially methylated and contributes to the regulation of
thegene inanallele specificmanner.Our studyhighlights the im-
portance of integrated analyses using independent datasets, par-
ticularly from genetic and epigenetic sources. The individual
analysis of these datasets of complex disease may identify
nominal significance of a given platform, however recognizing
Figure 6. A genetic variant in COL15A1 is associated with atherosclerosis, leads to reduced COL15A1 gene expression in human aorta and its methylation state is
correlatedwith disease. (A) Forty-two tag SNPswere selected to cover all of the known genetic variation inCOL15A1. These SNPswere genotyped in an atheroscler-
osis sample (CATHGEN)and allelic associationwith atherosclerosiswas assessedusingmultivariable logistic regressionmodeling adjusting for sex andknownCAD
risk factors. Significant (SNP38) and trending (SNP 41) SNPs are indicated with arrows. Underlined SmaI sites indicate sites that change DNA methylation with
passage. (B)COL15A1 gene expression was assessed in aorta tissue regardless of disease and the data were grouped by genotype. C allele carriers have a significant
reduction in COL15A1 gene expression. (C) The C allele of rs4142986 is the minor allele and creates a putative DNA methylation site in a region of the gene
that changes methylation with age. DNA methylation at rs4142986 was measured in aorta samples scored for disease (Sudan IV). DNA Methylation (%) is
plotted versus disease for individuals of each genotype. There is a significant correlation with disease and increased methylation. ‡P, mixed model (see methods);
†P, Pearson’s correlation, two-tailed.
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the intersection of genetic predisposition, aberrant epigenetic
regulation and the functional surrogacy of differential expres-
sion, will facilitate the identification of novel genes and func-
tionally important pathways, even in a model with the
complexity of aging-dependent cardiovascular disease.
MATERIALS AND METHODS
Aortic SMC culture
Cryopreserved human aortic SMCs lot #6F3685 (derived from a
22-year old, Caucasianmale) were obtained from Lonza (Walk-
ersville,MD) at Passage 3 and cultured atDukeUniversity.Cells
were grown in T-75 SoLo Flasks NunclonTMD (NUNC, Roches-
ter, NY, USA) according to manufacturer’s instructions (www.
lonzabioscience.com). The initial proliferating culture was
grown to 80% confluency in one T75 flask. These cells were
counted one day after plating to determine the starting number
of viable plated cells (300 000 cells), which was used to deter-
mine starting PD at Passage 5 (22 PD). From this initial
culture, 3500 cells /cm2 were plated in three separate flasks
and were incubated at 378C for 96 h (80% confluency).
Media was replaced every 48 h. Cells were grown in this
fashion and reached 80% confluency in 4 days until Passage
14. At this point, cells were given additional time to reach 80%
confluency as indicated. Each flask represents an individual bio-
logical replicate of the same genetic background, and these three
replicates were used for the genome screen. Cryopreserved
human aortic SMCs lot #7F4356 (derived from a 22-year old,
Caucasian male) were obtained from Lonza (Walkersville,
MD) at Passage 3 and cultured at the University of Virginia
until Passage 8 under the same conditions described.
AoSMC DNA and RNA sample isolation
DNAwas isolatedusing theGentraPuregeneCellkit fromQiagen
(Valencia, CA,USA), andRNAwas isolated usingRNAlater and
a Ribopure kit both from Ambion/Applied Biosystems (Foster
City, CA). Complementary DNA (cDNA) was synthesized
using an Illumina TotalPrep RNA amplification kit from
Ambion/Applied Biosystems. Additionally, all COL15A1 find-
ings were also confirmed using a different AoSMC line, lot
7F4356.
LUMA assay for global DNA methylation
ALUMAassaywas performed as described inKarimi et al. (20).
Briefly, 200 ng of high-quality genomic DNA was double
digested with HpaII and EcoRI or MspI and EcoRI (New
England Biolabs, Ipswich, MA, USA) for 4 h at 378C. Pyrose-
quencing was performed using a Pyromark Q24 (Qiagen) in an
SNP mode assay with the following sequence to be analyzed:
ACTCGA. Each reaction was run in triplicate.
5-Aza-2′-deoxycytidine treatment
5-Aza-2′-deoxycytidine was obtained from Sigma-Aldrich
(St Louis, MO, USA) and diluted into SMG-2 media to 5 mM.
Passage 5 and 8 cells were cultured to 70% confluence, and
media with or without (mock control) 5-Aza-2′-deoxycytidine
was added to theflask.Cellswere cultured for 72 h andharvested
for nucleic acid purification.
Epigenetic screen
Methylated DNA from AoSMCs was isolated from cells (lot
#6F3685) at Passages 5–8. DNAs from test and reference
samples were prepared by the MCA method (47). Briefly, DNA
was digested with the methylation-sensitive restriction enzyme,
SmaI, generating blunt end cuts followed by digestion with the
methylation-insensitive restriction enzyme, XmaI, generating
sticky ends. Adapters are ligated to the sticky ends following
XmaI digest and the DNA is amplified as described (22) by a
PCR using primers that anneal to the adapter sequences. The
amplicons from the sample and control are then individually
labeled with Cy5 and Cy3 fluorescent dyes. Passage 5 DNA was
labeled with Cy5 and Cy3 and co-hybridized to the genomic tile-
path microarray, this served as our experimental control of no
change.Clones thatperformedpoorly in the self–selfexperiments
were discarded from the dataset (log2 ratio +/2 0.4, variance
.0.3). Three biological replicates of the same genetic back-
ground at Passages 5 versus 8were labeledwith Cy3 andCy5, re-
spectively, and co-hybridized to a genomicmicroarray (23). Data
were collected using an Axon scanner and a Bluefuse microarray
analysis program was used for data processing. The program
incorporates Bayesian statistical models in the analysis and pro-
vides: (1) amore uniform analysis of the data by eliminating vari-
ability introduced by human examination, (ii) more reproducible
results across experiments by normalizing experimental variation
(Block Lowess) and (iii) an increased amount of usable data. The
software exports the results in excel format. For each clone on the
array, a normalized intensity value and user defined log2 ratios
(log2[p8 intensity/p5 intensity]) were exported from BlueFuse
and the median log2 ratio value for each experimental replicate
was calculated. The control experiment, Passage 5 versus
Passage 5, the sameDNA hybridized to itself provided a baseline
of clone variation. The experimental data (Passages 5 versus 8)
were compared using a two-tailed t-test to identify significantly
differentiallymethylated clones.We then correlated the sequence
contained within these differentially methylated clones to the
SmaI sites within the sequence, as well as localized annotated
genes and predicted CpG islands, promoters and regulatory
regions.
Gene expression using Illumina Beadarray
Global gene expression profiling was conducted for Passages
5 and 8 SMCs using Illumina Human WG-6 V2 BeadArrays as
described by the manufacturer (Illumina, Inc., San Diego, CA,
USA). Rank invariant normalization was applied to the raw
data, and a two-tailed t-test was used to identify significant
changes in gene expression between the two time points.
DNA methylation analysis
DNA(200 ng)was bisulfite treated using aMethylCode bisulfite
conversion kit from Invitrogen (Carlsbad, CA, USA), and
primers were designed to amplify each SmaI site within
COL15A1. A PCR was performed on bisulfite converted DNA
from Passages 5 and 8 with the following reaction conditions:
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958C for 10 min (min), 35 cycles of 958C for 1 min, 558C for
1 min, 728C for 3 min, 728C for 10 min. PCRs were run on a
2% agarose gel and single bands corresponding to the predicted
molecular weight of the product were extracted. DNA was iso-
lated from gel fragments using a Qiagen Gel purification kit.
DNA was TOPO-TA cloned using Invitrogen’s TOPO-TA
cloning kit. Twenty-four clones were picked and sequenced
for each site. A minimum of 20 clones were used to determine
percent methylation at each site. Primer sequences for each
site are listed in Supplementary Material, Table S5.
Quantitative RT-PCR
Applied Biosystems Taqman Gene expression assays were used
to perform quantitative RT-PCR (COL15A1- Hs01559630_m1,
CCDN1- Hs00765553_m1, DNMT1-Hs00154749, B2M-Hs
99999907_m1 and GAPDH - Hs02758991_g1). The following
reaction components were used for each probe: 2 ml cDNA,
5 ml Custom TaqMan SNP master mix (Applied Biosystems),
0.5 ml assay and 2.5 ml water. Reactions were performed in a
single 384-well plate in triplicate using an ABI PRISMw
7900HT sequence Detection System. PCR conditions were as
follows: Step 1: 508C for 2 min, Step 2: 958C for 10 min, Step
3: 40 cycles of 958C for 15 s followedby608Cfor 1 min. Expres-
sion relative to GAPDH or B2M was calculated using 2DDCt 42.
Proliferation and migration assays
Cell proliferation assays were performed using Promega’s Cell-
Titer 96 Aqueous One Solution Cell Proliferation assay
(Madison,WI,USA) according to themanufacturer’s directions.
Cell migration assays were performed on Millipore Multi-
Screen-MIC plates containing 8 mm pores. Cells at Passage 5
or 6 were grown to 70% confluence and then switched to serum-
free media. A cell suspension (1 × 105 cells/ml, 150 ml) was
added to the upper well in serum-free media containing 0.1%
BSA (Sigma). Fibronectin (5 mg/ml, Sigma) was added to the
bottom chamber in serum-free media with 0.1% BSA
(FN-induced chemotaxis). The chambers were incubated at
378C in aCO2 incubator for 18 h, and fixed in 4% formaldehyde.
The non-invaded cells were removed from the upper wells and
the invaded cells were stained with 0.2%Crystal Violet solution
in 7% ethanol. Cells from 8 to 10 randomly chosen high-power
fields (magnification ×20) on the lower surface of the filter
were counted (48).
COL15A1 western analysis
Cellswere lysed inRIPAwith protease inhibitors. Cleared lysates
were reduced and electrophoresed on a 3–8% NuPAGE Tris
Acetate gel. Proteins were then transferred onto a nitrocellulose
membrane. After an initial blocking with 3% dried milk in
TBST, membranes were probed with 1 mg/ml Goat
anti-COL15A1 (C-20) or anti-DNMT1 (H-300) (both from
Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted in
3% BSA and incubated overnight at 48C. The membranes were
then washed and incubated with a Donkey anti Goat IR-Dye
800CW (LI-COR Biosciences, Lincoln, NE, USA) diluted in
blocking buffer. Membranes were then analyzed using the
ODYSSEY Infrared Imaging System (LI-COR Biosciences).
Animals
Animal protocols were approved by the Animal Care and Use
Committee at the University of Virginia. To accelerate athero-
sclerosis, mice were fed a Western atherogenic diet (Harlan
Teklad, Madison, WI, USA) containing 21.2% fat by weight
(0.2% by weight cholesterol, 17.3% by weight protein and
48.5% byweight carbohydrate) for 13weeks (RNAquantiation)
or 18 weeks (immunostaining).
Mouse aorta and liver samples and expression
Apoe null mice (male, 8 weeks of age) were obtained from The
Jackson laboratory (Bar Harbor, ME, USA). Mice were fed a
Western atherogenic diet for 13 weeks. C57BL/6 mice (male,
21 weeks of age) on a chow diet were used as a control. The
Fast Prep FP120 (Q-Biogene) was used to homogenize tissues,
and total RNA was prepared from aorta and liver. Col15a1
expression in each sample was normalized to Gapdh levels.
Human donor aorta samples and expression
Human aorta samples were collected from heart transplant
donors as previously described (24,26). The studywas approved
by the Duke institutional review committee and all participants
gave informed consent. DNA and RNA were isolated from
each sample. Eighty-eight samples in total were analyzed repre-
senting 58 unique samples, as 30 individuals had more than one
sample. As harvested tissue was obtained from deceased heart
donors, the clinical data associated with these aortas are very
limited and consists of age, sex and self-reported race (49). All
samples were scored for the presence of raised lesions and
stainedwith Sudan IV to detect lipid accumulation as previously
reported (49). Cases (n ¼ 26) and controls (n ¼ 62) were deter-
minedusing the followingcriteria: anyevidence of raised lesions
and Sudan IV staining was considered a case, while individuals
with no raised lesions (RL ¼ 0) and no Sudan IV staining were
considered controls. We were interested in the mean expression
level of COL15A1 in the two groups, the standard deviation and
then the test of significance of this difference.We performed the
test using amixedmodel to account for the fact that several indi-
viduals havemore than one tissue sample and thusmore than one
expression value. We also adjusted for age, sex and race in the
mixed model. Aorta genotyping was performed using Applied
Biosystems Taqman allelic discrimination assays, and expres-
sion profiling was performed using Affymetrix GeneChip
U95Av2 (Affymetrix, Santa Clara, CA, USA). Expression
signal intensity values were log2 transformed and normalized
using quantile normalization. We analyzed cis effects of
COL15A1 variants on COL15A1 expression using the Affyme-
trix tag 38427_at, representing the 3′ end of COL15A1.
Because some subjects had multiple samples while others did
not, we treated each individual and sample separately. The ex-
pression level of the tag was modeled using multiple linear re-
gression including age, sex, race and additive genotype. To
account for repeated measures (i.e. multiple sections per sub-
jects) and as a validation, a mixed model as implemented in
the SAS PROC MIXED procedure was utilized (SAS Institute
Inc., Cary, NC, USA).
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COL15A1 immunostaining
Transverse sections of the aortic root were taken from a wild-
type (C57/BL6) chow-fed mouse and an Apoe null mouse fed
Western diet for 18 weeks (kindly provided by Dr Coleen
McNamara, UVA). Immunostaining was performed on 4 mm
paraffin sections that were deparaffinized and incubated in
20 mg/ml proteinase K (Sigma P6556) for 3 min at room
temperature, followedby blockingwith 2%normal sera and sub-
sequent incubation with 5 mg/ml goat anti-human COL15A1
(C-20, Santa Cruz Biotechnology, Inc.) or biotinylated anti-a
SMA (Sigma) overnight at 48C. After incubation with the
AP–ABC complexes, immunoreactivity was visualized by in-
cubation with alkaline phosphatase substrate (Vector Labs).
No antibody control experiments were performed in an identical
fashion as described for COL15A1 staining, except that
COL15A1 antibody was not added.
CAD case–control sample (CATHGEN)
CATHGEN participants (n ¼ 1279) were recruited sequentially
through the cardiac catheterization laboratories at Duke Univer-
sity Hospital (Durham, NC, USA) with approval from the Duke
Institutional ReviewBoard. All participants undergoing catheter-
izationwereofferedparticipation in thestudyandsignedinformed
consent. Medical history and clinical data were collected and
stored in the Duke Information System for Cardiovascular Care
databasemaintained at theDukeClinicalResearch Institute. Con-
trols and cases were chosen on the basis of extent of CADasmea-
sured by CADi. CADi is a numerical summary of coronary
angiographic data that incorporates the extent and anatomical dis-
tribution of coronary disease. Affection status was determined by
the presence of significant CAD defined as a CADi ≥ 74, equiva-
lent to three-vessel diseasewith at least a 95%stenosis in theprox-
imal left anterior descending coronary artery, as we have used for
previous studies (26,50). A comparison of clinical characteristics
betweenCATHGENcases andunaffectedcontrols haspreviously
been presented (50). An aged Caucasian sample was used for the
analysis. Medical records were reviewed to determine the age of
onset (AOO) of CAD, i.e. the age at first documented surgical
or percutaneous coronary revascularization procedure, myocar-
dial infarction (MI) or cardiac catheterization meeting the above-
defined CADi thresholds. The CATHGEN cases AOO. 55
years (n ¼ 250) and controls had an age at catheterization ≥60
years (n ¼ 220) and had no CAD as defined by coronary angiog-
raphy and no documented history of MI, heart transplant, periph-
eral or cerebrovascular disease, or interventional or surgical
coronary revascularization procedures.
SNP genotyping
The Human HapMap project (Release 24/phaseII Nov08) data
and the algorithm Tagger (51) were used to generate tagSNPs
forRP11-192E23 (clone identified in epigenetic screen, contains
COL15A1) using data derived from the CEU population (Utah
residents with ancestry from northern and western Europe),
given that the CATHGEN sample used was Caucasian (26).
A total of 42SNPswere genotyped at theCenter forHumanGen-
etics using Taqman allelic discrimination assays. A total of 15
quality control samples—composed of six reference genotype
controls in duplicate, two CEPH pedigree individuals and one
no-template sample, were included in each quadrant of the
384-well plate. SNPs that showed mismatches on quality
control samples were reviewed by an independent genotyping
supervisor for potential genotyping errors. All SNPs examined
were successfully genotyped for 95% or more of the individuals
in the study. Error rate estimates for SNPs meeting the quality
control benchmarks were determined to be ,0.2%.
SNP statistical analysis
All SNPs were tested for deviations (P ≤ 0.0001) from Hardy–
Weinberg equilibrium (HWE) in the affected and unaffected
groups. Two SNPs deviated from HWE, rs7470221 (cases)
and rs1413294 (cases). Neither of these SNPs was statistically
significant in our association analysis. LD between pairs of
SNPs (r2 . 0.7) was assessed using the Graphical Overview
of Linkage Disequilibrium package (52). No strong LD (r2.
0.7) was found, confirming the tagSNP selection. Genetic asso-
ciation in theCATHGENcases and controlswas evaluated using
multivariable logistic regression modeling, including the SNP
genotype coded for an additive genetic model, i.e. zero, one or
two copies of the minor allele. The model was adjusted for
sex, and known CAD risk factors (history of hypertension,
history of diabetesmellitus, bodymass index, history of dyslipi-
demia and smoking history) as covariates. These adjustments
could hypothetically allow us to control for competing genetic
pathways that are independent risk factors for CAD, thereby
allowing us to detect a separate CAD genetic effect. SAS 9.1
(SAS Institute, Cary, NC,USA)was used for statistical analysis.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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